Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Propranolol for Surgically Inaccessible Cavernous Malformations
NCT03523650Phase 1Unknown
- Sponsor
- University of Virginia
- Start
- Feb 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in cerebral cavernous malformation (CCM) and cavernous malformation (CCM) comparing Propranolol Group with Placebo Group (2 arms). Primary endpoint: Number of symptomatic and silent hemorrhages on MRI at 36 months. Status: unknown.
02
Drugs
propranolol
03
Conditions
cerebral cavernous malformation (CCM)cavernous malformation (CCM)
Beyond the preview
Go deeper on NCT03523650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03523650.